Vol 46, No 4 (2015)
Prace poglądowe / Reviews
Published online: 2015-09-01

open access

Page views 185
Article views/downloads 515
Get Citation

Connect on Social Media

Connect on Social Media

Ruxolinib in therapy if myeloproliferative neoplasms Ph(-)

Tomasz Wróbel
DOI: 10.1016/j.achaem.2015.07.004
Acta Haematol Pol 2015;46(4):292-298.

Abstract

Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis and post-polycythaemia vera myelofibrosis and post-essential thrombocytaemia myelofibrosis. The article is a summary of current clinical data with ruxolitinib therapy both in myelofibrosis and in other Ph-negative myeloproliferative neoplasms.

Article available in PDF format

View PDF (Polish) Download PDF file